AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interferon alpha/beta receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P17181

UPID:

INAR1_HUMAN

Alternative names:

Cytokine receptor class-II member 1; Cytokine receptor family 2 member 1; Type I interferon receptor 1

Alternative UPACC:

P17181; B2R6L9; B4DNT3; D3DSF0; Q53GW9; Q53H11; Q6PKD7; Q7M4L2; Q8WTZ2

Background:

Interferon alpha/beta receptor 1, also known as Cytokine receptor class-II member 1, plays a pivotal role in the immune response. It forms a heterodimeric receptor with IFNAR2 for type I interferons, activating the JAK-STAT signaling pathway, which is crucial for the transcriptional regulation of interferon-regulated genes.

Therapeutic significance:

The protein's involvement in Immunodeficiency 106, characterized by increased susceptibility to viral infections and severe reactions to certain vaccines, highlights its therapeutic potential. Targeting this receptor could lead to innovative treatments for viral infections and immune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.